We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » REVISED CRESTOR LABELING IN EUROPE TRIGGERS FDA ADVISORY
REVISED CRESTOR LABELING IN EUROPE TRIGGERS FDA ADVISORY
June 9, 2004
The FDA has issued a public health advisory to healthcare providers after the European Medicines Evaluation Agency mandated that AstraZeneca make changes to labeling for its cholesterol drug Crestor.